Zynerba Pharmaceuticals Current Ratio 2014-2018 | ZYNE

Zynerba Pharmaceuticals current ratio from 2014 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Zynerba Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $0.07B $0.01B 7.95
2018-06-30 $0.05B $0.01B 4.34
2018-03-31 $0.06B $0.01B 6.51
2017-12-31 $0.07B $0.01B 9.17
2017-09-30 $0.07B $0.01B 8.65
2017-06-30 $0.08B $0.01B 9.72
2017-03-31 $0.08B $0.01B 12.01
2016-12-31 $0.04B $0.01B 5.23
2016-09-30 $0.04B $0.01B 7.18
2016-06-30 $0.04B $0.01B 7.07
2016-03-31 $0.04B $0.00B 13.22
2015-12-31 $0.04B $0.00B 11.03
2015-09-30 $0.05B $0.00B 17.27
2015-06-30 $0.01B $0.00B 2.27
2015-03-31 $0.01B $0.00B 3.08
2014-12-31 $0.01B $0.00B 3.69
2014-09-30 $0.00B $0.00B 0.00
2014-06-30 $0.00B $0.00B 0.00
2014-03-31 $0.00B $0.00B 0.00
2013-12-31 $0.00B $0.00B 0.44
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.089B $0.000B
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $45.888B 8.26
Teva Pharmaceutical Industries (TEVA) Israel $18.324B 6.32
Mylan (MYL) United Kingdom $16.552B 6.82
Bausch Health Cos (BHC) Canada $8.810B 6.38
Dr Reddy's Laboratories (RDY) India $6.044B 24.11
Supernus Pharmaceuticals (SUPN) United States $1.990B 18.86
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.827B 3.05
Amphastar Pharmaceuticals (AMPH) United States $1.121B 121.55
Homology Medicines (FIXX) United States $0.901B 0.00
CymaBay Therapeutics (CBAY) United States $0.612B 0.00
Assembly Biosciences (ASMB) United States $0.573B 0.00
Akorn (AKRX) United States $0.558B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.402B 0.00
Voyager Therapeutics (VYGR) United States $0.351B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.292B 0.00
Sol-Gel Technologies (SLGL) Israel $0.123B 0.00
Teligent (TLGT) United States $0.087B 0.00
Acasti Pharma (ACST) Canada $0.072B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.062B 0.00
Evoke Pharma (EVOK) United States $0.056B 0.00
Agile Therapeutics (AGRX) United States $0.035B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00
China Pharma Holdings (CPHI) China $0.012B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.005B 0.00